Loading
A phase 1 trial of INV-1120 run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT04443088 by Shenzhen Ionova Life Sciences Co., Ltd., with 78 participants planned, started 2020-06-26. Conditions recorded: Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult and Tumor, Solid. Interventions recorded: INV-1120 and Pembrolizumab.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/